6p21.33
Selected marker rs2844682. This is a chromosome-region label, not an additional gene.
Selected genetic markers that can inform medication choice, dosing and monitoring when evidence-based gene–drug guidance is available.
Understanding the test
Pharmacogenomics explores how inherited variation can influence medicine response. The selected-marker panel includes 44 named genes plus two additional locus entries. Results may support prescribing decisions where a tested variant has established clinical guidance. Targeted testing and PGx within exome or genome workflows have different scopes. A clinician interprets findings alongside medicines, health history and other factors; inclusion in the panel does not make every marker clinically actionable.
Selected-variant genotyping. Exome-based PGx uses targeted enrichment with NGS and qPCR for CYP2D6 copy number; genome-based PGx uses PCR-free NGS. The selected workflow determines scope.
What is included
Selected marker rs2844682. This is a chromosome-region label, not an additional gene.
Selected marker rs3913290. This is a locus entry, not an additional gene.
An additional selected marker on chromosome 19, shown separately from the gene list.
Targeted enrichment with NGS genotype calls and qPCR for CYP2D6 copy number; the order specifies the selected target content.
PCR-free genome sequencing with CYP2D6 copy-number analysis from genome data; reportable alleles and complex findings depend on the validated workflow.
Connect the gene to the clinical question
Explore each gene’s full name, associated conditions and clinical relevance. Open a row for function, inheritance, evidence and testing notes.
44 named genes are listed, plus the separate loci 6p21.33 and intergenic. Testing assesses selected markers associated with these genes or regions rather than sequencing every listed gene in full.
The medication notes describe gene–drug context. This selected-marker assay may not cover all variants or combinations needed for a prescribing recommendation.
44 genes in this panel
How to read the evidenceRelevant to drug transport, but the two listed markers do not provide a general prediction of treatment response.
Research association
Selected transport-related markers are not a validated universal drug-sensitivity score. Use medicine-specific evidence before considering any clinical application.
The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes.
Function summary: NCBI Gene · ABCB1Reduced transporter function can increase rosuvastatin exposure; CPIC provides medicine-specific guidance.
Guideline-supported gene–medicine association
The listed rs2231142 marker is relevant to rosuvastatin guidance. A result must be interpreted with the clinical report, other relevant genes and the intended medicine.
The membrane-associated protein encoded by this gene is included in the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes.
Function summary: NCBI Gene · ABCG2Medicines discussed in guidance: Rosuvastatin. Guidance is variant- and medicine-specific.
A candidate marker for differences in medication response; a receptor role alone does not establish a prescribing recommendation.
Research association
The selected variants should not be used alone to choose an ADHD medicine or predict whether treatment will work.
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. The alpha-2-adrenergic receptors are a type of adrenergic receptors (for adrenaline or epinephrine), which inhibit adenylate cyclase.
Function summary: NCBI Gene · ADRA2AReceptor variation has been studied in treatment response, but the listed marker does not provide a general prescribing rule.
Research association
Do not infer bronchodilator or beta-blocker effectiveness from this single marker. Clinical response and the indication remain essential.
This gene encodes beta-2-adrenergic receptor which is a member of the G protein-coupled receptor superfamily. This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel Ca(V)1.2.
Function summary: NCBI Gene · ADRB2This entry is an assay marker, not an established medication-response gene result.
Assay marker
The supplied identifier, hCV990000001, is an assay identifier rather than a standard rs identifier. Its inclusion does not establish whole-gene analysis, an enamel-disorder diagnosis or a validated sex-chromosome assessment.
This gene encodes a member of the amelogenin family of extracellular matrix proteins. Amelogenins are involved in biomineralization during tooth enamel development.
Function summary: NCBI Gene · AMELXThe included marker identifier is hCV990000001. It is not an rs identifier or a complete gene-sequencing claim.
Its Taq1A marker has been studied in dopamine-related traits and medication response.
Research association
rs1800497 is an ANKK1-region marker, not a direct measurement of dopamine-receptor function. It does not independently establish a psychiatric diagnosis or a prescribing recommendation.
The protein encoded by this gene belongs to the Ser/Thr protein kinase family, and protein kinase superfamily involved in signal transduction pathways. This gene is closely linked to DRD2 gene (GeneID:1813) on chr 11, and a well studied restriction fragment length polymorphism (RFLP) designated TaqIA, was originally associated with the DRD2 gene, however, later was determined to be located in exon 8 of ANKK1 gene (PMIDs: 18621654, 15146457), where it causes a nonconservative amino acid substitution.
Function summary: NCBI Gene · ANKK1APOE ε4 status is relevant to the risk of amyloid-related imaging abnormalities with certain anti-amyloid medicines.
Medicine-label association
The two listed markers are used to determine common APOE isoforms. Results require careful clinical interpretation and do not diagnose Alzheimer disease or establish that a person will develop it.
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents.
Function summary: NCBI Gene · APOEMedicines discussed in guidance: Lecanemab, Donanemab. Guidance is variant- and medicine-specific.
The listed rs11212617 is used as a regional association marker; its label should not be read as proof that this gene causes a drug response.
Research association
Regional association studies do not establish a stand-alone prescribing recommendation. This marker is not comprehensive analysis of C11orf65 or nearby genes.
Predicted to be involved in negative regulation of mitochondrial fission and obsolete negative regulation of protein targeting to mitochondrion. Predicted to be located in cytosol and mitochondrial outer membrane.
Function summary: NCBI Gene · C11orf65rs11212617 is an associated regional marker; association labels do not necessarily identify a variant’s physical gene location.
Included as a candidate association marker; its structural role does not itself indicate medicine choice or dose.
Research association
A result for the listed common marker does not diagnose a collagen disorder or establish a stand-alone prescribing recommendation.
This gene encodes member of the collagen family which is thought to contribute to the stabilization of myotendinous junctions and strengthen skeletal muscle attachments during contractile activity. It belongs to the fibril-associated collagens with interrupted triple helix (FACIT) subset of the collagen superfamily, which associate with collagen fibers through their C-terminal collagenous domains and mediate protein-protein interactions through their N-terminal noncollagenous domains.
Function summary: NCBI Gene · COL22A1Studied in pain and opioid response, but CPIC does not provide opioid prescribing recommendations based on COMT.
Research association
The rs4680 result should not be used by itself to select an opioid or determine its dose.
Catechol-O-methyltransferase catalyzes the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, epinephrine, and norepinephrine. This O-methylation results in one of the major degradative pathways of the catecholamine transmitters.
Function summary: NCBI Gene · COMTThe selected common marker is an association marker and is not a diagnostic assessment for coenzyme Q deficiency.
Research association
A single common variant does not establish a need for supplements or a change in medication. Rare disease-causing variants require a different diagnostic assessment.
This gene encodes an enzyme that functions in the final steps in the biosynthesis of CoQ (ubiquinone), a redox carrier in the mitochondrial respiratory chain and a lipid-soluble antioxidant. This enzyme, which is part of the coenzyme Q10 pathway, catalyzes the prenylation of parahydroxybenzoate with an all-trans polyprenyl group.
Function summary: NCBI Gene · COQ2Studied as a candidate treatment-response marker; no stand-alone prescribing recommendation is established here.
Research association
Receptor biology and a single association marker are not sufficient to predict treatment benefit or adverse effects.
The protein encoded by this gene belongs to the G-protein coupled receptor 2 family, and the subfamily of corticotropin releasing hormone receptor. This receptor shows high affinity for corticotropin releasing hormone (CRH), and also binds CRH-related peptides such as urocortin.
Function summary: NCBI Gene · CRHR2Enzyme activity is affected by medicines, smoking and other environmental factors as well as genetics.
Drug-metabolism gene; limited marker interpretation
The two listed markers do not by themselves establish a reliable metaboliser phenotype or a medicine dose. Clinical factors and medicine-specific monitoring remain important.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The protein encoded by this gene localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke.
Function summary: NCBI Gene · CYP1A2Genetic variation can affect nicotine metabolism, but the listed markers do not independently select a smoking-cessation treatment.
Drug-metabolism gene; limited marker interpretation
Selected-marker testing does not fully assess this complex gene or establish a general metaboliser classification.
This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital.
Function summary: NCBI Gene · CYP2A6Clinically interpreted CYP2B6 variation can inform efavirenz and sertraline prescribing.
Guideline-supported gene–medicine association
The two listed markers are not a complete CYP2B6 allele assessment. A validated genotype-to-phenotype interpretation is needed before applying a prescribing guideline.
This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital.
Function summary: NCBI Gene · CYP2B6Medicines discussed in guidance: Efavirenz, Sertraline. Guidance is variant- and medicine-specific.
Metaboliser status can affect clopidogrel activation and exposure to medicines such as citalopram and voriconazole.
Guideline-supported gene–medicine association
The two listed markers do not establish a comprehensive metaboliser phenotype. A prescribing decision requires an assay that covers the relevant functional alleles and a validated clinical interpretation.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes.
Function summary: NCBI Gene · CYP2C19Medicines discussed in guidance: Clopidogrel, Citalopram, Voriconazole. Guidance is variant- and medicine-specific.
CYP2C8 variation has been studied in NSAID metabolism; CPIC does not recommend NSAID dosing based on CYP2C8.
Drug-metabolism gene; limited clinical actionability
The two selected markers do not establish a complete metaboliser phenotype or an independent NSAID prescribing recommendation.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital.
Function summary: NCBI Gene · CYP2C8Reduced enzyme function can affect exposure to warfarin, phenytoin and some NSAIDs.
Guideline-supported gene–medicine association
The listed common variants cover only part of CYP2C9 variation. An unremarkable selected-marker result does not exclude other reduced-function alleles; apply medicine-specific guidance using the full clinical report.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin.
Function summary: NCBI Gene · CYP2C9Medicines discussed in guidance: Warfarin, Phenytoin, Celecoxib. Guidance is variant- and medicine-specific.
Metaboliser status can influence codeine and tramadol activation and atomoxetine exposure.
Guideline-supported gene–medicine association
The listed rs1065852 marker and exon 9 copy-number target do not establish a complete star-allele, hybrid-gene or metaboliser assessment. Medicines that inhibit CYP2D6 can also alter the functional phenotype.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics.
Function summary: NCBI Gene · CYP2D6Medicines discussed in guidance: Codeine, Tramadol, Atomoxetine. Guidance is variant- and medicine-specific.
Selected targets include rs1065852 and CYP2D6 XN Exon 9. These do not define a complete star-allele or hybrid-gene assay. Copy-number methods differ between exome and genome workflows.
The selected variants are research markers, not a general test of susceptibility to medicine toxicity.
Research association
A marker result should not independently determine a medicine or dose, and it does not replace clinical assessment of liver health or exposure.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum and is induced by ethanol, the diabetic state, and starvation.
Function summary: NCBI Gene · CYP2E1Its activity is strongly influenced by interacting medicines and other factors; gene involvement alone does not make every variant actionable.
Drug-metabolism gene; limited marker interpretation
The two listed markers do not constitute comprehensive CYP3A4 analysis or a validated general metaboliser profile. Any application must be specific to the medicine and the variants actually measured.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents.
Function summary: NCBI Gene · CYP3A4CYP3A5 expression status can inform initial tacrolimus prescribing alongside therapeutic drug monitoring.
Guideline-supported gene–medicine association
The two listed markers alone do not fully establish CYP3A5 expression status. Tacrolimus guidance requires an adequately characterised genotype and continued blood-level monitoring.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The encoded protein metabolizes drugs as well as the steroid hormones testosterone and progesterone.
Function summary: NCBI Gene · CYP3A5Medicines discussed in guidance: Tacrolimus. Guidance is variant- and medicine-specific.
CYP4F2 variation can contribute to warfarin dose requirements.
Guideline-supported gene–medicine association
This marker is only one component of a warfarin assessment. Other genes, clinical factors and INR monitoring remain necessary.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum.
Function summary: NCBI Gene · CYP4F2Medicines discussed in guidance: Warfarin. Guidance is variant- and medicine-specific.
Common variants have been studied in psychiatric treatment response, but these markers do not provide a stand-alone prescribing recommendation.
Research association
A receptor-gene result is not a diagnosis and does not independently predict which antipsychotic or other psychiatric medicine will work.
This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor inhibits adenylyl cyclase activity.
Function summary: NCBI Gene · DRD2Its role in metabolism has prompted drug-response studies; the selected marker is not a general measure of detoxification capacity.
Research association
The rs1051740 marker alone does not establish a medicine choice, dose or overall risk of adverse drug reactions.
Epoxide hydrolase is a critical biotransformation enzyme that converts epoxides from the degradation of aromatic compounds to trans-dihydrodiols which can be conjugated and excreted from the body. Epoxide hydrolase functions in both the activation and detoxification of epoxides.
Function summary: NCBI Gene · EPHX1The listed rs1799963 variant is associated with inherited susceptibility to venous blood clots.
Inherited clotting-risk marker
This is a thrombophilia marker rather than a drug-metabolism result. It does not on its own establish a need for anticoagulation or determine an anticoagulant dose.
This gene encodes the prothrombin protein (also known as coagulation factor II). This protein is proteolytically cleaved in multiple steps to form the activated serine protease thrombin.
Function summary: NCBI Gene · F2The listed rs6025 variant corresponds to factor V Leiden, an inherited risk factor for venous thrombosis.
Inherited clotting-risk marker
Its relevance depends on personal and family history and other risk factors. It does not independently establish a need for anticoagulation or determine a drug dose.
This gene encodes an essential cofactor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation.
Function summary: NCBI Gene · F5The enzyme is a biological target of some osteoporosis medicines, but target biology does not make the selected variant a prescribing test.
Research association
The rs2297480 marker should not be used alone to select an osteoporosis treatment or predict treatment response.
This gene encodes an enzyme that catalyzes the production of geranyl pyrophosphate and farnesyl pyrophosphate from isopentenyl pyrophosphate and dimethylallyl pyrophosphate. The resulting product, farnesyl pyrophosphate, is a key intermediate in cholesterol and sterol biosynthesis, a substrate for protein farnesylation and geranylgeranylation, and a ligand or agonist for certain hormone receptors and growth receptors.
Function summary: NCBI Gene · FDPSIncluded as a candidate association marker; the gene’s role does not establish a medicine-specific prescribing rule.
Research association
The selected marker is not a comprehensive test of this gene or nearby immune-region genes, and it does not establish HLA status.
This gene encodes an protein that localizes to the caveolae, which are small domains on the inner cell membranes. This protein plays a role in vesicle trafficking and cell morphology.
Function summary: NCBI Gene · FLOT1Investigated as a treatment-response marker; this does not establish a stand-alone psychiatric prescribing recommendation.
Research association
The listed common variant does not diagnose a psychiatric condition or reliably identify an effective antidepressant for an individual.
This gene encodes a protein that belongs to the glutamate-gated ionic channel family. Glutamate functions as the major excitatory neurotransmitter in the central nervous system through activation of ligand-gated ion channels and G protein-coupled membrane receptors.
Function summary: NCBI Gene · GRIK4Investigated in psychiatric treatment response, but the selected marker does not provide an independent prescribing recommendation.
Research association
rs6295 is an association marker, not a direct test of serotonin levels or a diagnosis of a psychiatric condition.
This gene encodes a G protein-coupled receptor for 5-hydroxytryptamine (serotonin), and belongs to the 5-hydroxytryptamine receptor subfamily. Serotonin has been implicated in a number of physiologic processes and pathologic conditions.
Function summary: NCBI Gene · HTR1ACPIC finds insufficient evidence to use HTR2A results for serotonin reuptake inhibitor prescribing.
Research association
The listed common variants should not be used alone to choose an antidepressant or determine its dose.
This gene encodes one of the receptors for serotonin, a neurotransmitter with many roles. Multiple transcript variants encoding different isoforms have been found for this gene.
Function summary: NCBI Gene · HTR2AStudied as a candidate marker for differences in treatment effects; the listed marker has no stand-alone prescribing recommendation here.
Research association
This entry covers rs3813929 only. It should not be used to make a diagnosis or independently select or change a psychiatric medicine.
This gene encodes a seven-transmembrane G-protein-coupled receptor. The encoded protein responds to signaling through the neurotransmitter serotonin.
Function summary: NCBI Gene · HTR2CThe listed marker is rs3813929.
An IFNL3-associated marker was used to help estimate response to older interferon-based hepatitis C regimens.
Regimen-specific association
rs12979860 is a regional marker in the IFNL3/IFNL4 area. Its historical interferon association should not be generalised to all current hepatitis C or antiviral treatments.
This gene encodes a cytokine distantly related to type I interferons and the IL-10 family. This gene, interleukin 28A (IL28A), and interleukin 29 (IL29) are three closely related cytokine genes that form a cytokine gene cluster on a chromosomal region mapped to 19q13.
Function summary: NCBI Gene · IFNL3Medicines discussed in guidance: Peginterferon alfa-2a, Peginterferon alfa-2b. Guidance is variant- and medicine-specific.
rs12979860 is an IFNL3-associated marker located in the nearby IFNL4 region. An association label does not necessarily identify a variant’s physical gene location.
Studied as a candidate marker of treatment-related blood effects; this does not establish a stand-alone prescribing rule.
Research association
The selected common marker does not assess every cause of drug-related anaemia or replace blood-count monitoring.
This gene encodes an inosine triphosphate pyrophosphohydrolase. The encoded protein hydrolyzes inosine triphosphate and deoxyinosine triphosphate to the monophosphate nucleotide and diphosphate.
Function summary: NCBI Gene · ITPAInvestigated in respiratory treatment response; the selected marker does not establish an independent prescribing recommendation.
Research association
A marker result cannot diagnose asthma or predict an individual’s response to a respiratory medicine on its own.
The MAPEG (Membrane Associated Proteins in Eicosanoid and Glutathione metabolism) family includes a number of human proteins, several of which are involved the production of leukotrienes. This gene encodes an enzyme that catalyzes the first step in the biosynthesis of cysteinyl leukotrienes, potent biological compounds derived from arachidonic acid.
Function summary: NCBI Gene · LTC4SIncluded as a candidate medication-response association marker.
Research association
The listed common variant does not establish a general pain-response profile or an independent opioid prescribing recommendation.
Enables ATPase binding activity; Hsp70 protein binding activity; and protein-lysine N-methyltransferase activity. Involved in negative regulation of protein folding and protein methylation.
Function summary: NCBI Gene · METTL21AThe two common variants are not equivalent to rare, disease-causing MTHFR deficiency and do not alone establish a prescribing recommendation.
Common metabolic variants; limited prescribing relevance
Do not infer a need for supplements, an anticoagulant or a particular medicine solely from these markers. The clinical question and relevant biochemical findings require separate assessment.
The protein encoded by this gene catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Function summary: NCBI Gene · MTHFRCPIC does not provide opioid prescribing recommendations based on OPRM1 because the evidence is insufficient.
Research association
The rs1799971 marker alone should not determine opioid choice, dose or an individual’s expected pain relief.
This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins.
Function summary: NCBI Gene · OPRM1Rare disease-causing SCN1A variants can be important in epilepsy, but the listed common marker is a different type of finding.
Common association marker; not diagnostic sequencing
Testing rs3812718 alone does not diagnose an SCN1A-related epilepsy or support treatment rules used for pathogenic SCN1A variants.
Voltage-dependent sodium channels are heteromeric complexes that regulate sodium exchange between intracellular and extracellular spaces and are essential for the generation and propagation of action potentials in muscle cells and neurons. Each sodium channel is composed of a large pore-forming, glycosylated alpha subunit and two smaller beta subunits.
Function summary: NCBI Gene · SCN1AStudied in treatment-response research; the two selected markers do not establish an independent prescribing recommendation.
Research association
A transporter association marker does not diagnose ADHD or reliably determine an individual’s response to an ADHD medicine.
This gene encodes a member of the sodium:neurotransmitter symporter family. This member is a multi-pass membrane protein, which is responsible for reuptake of norepinephrine into presynaptic nerve terminals and is a regulator of norepinephrine homeostasis.
Function summary: NCBI Gene · SLC6A2Reduced transporter function can increase statin exposure and the risk of muscle adverse effects.
Guideline-supported gene–medicine association
The listed rs4149056 marker is clinically relevant, but recommendations differ between statins. Interpretation should use the full report and other risk factors.
This gene encodes a liver-specific member of the organic anion transporter family. The encoded protein is a transmembrane receptor that mediates the sodium-independent uptake of numerous endogenous compounds including bilirubin, 17-beta-glucuronosyl estradiol and leukotriene C4.
Function summary: NCBI Gene · SLCO1B1Medicines discussed in guidance: Simvastatin, Atorvastatin, Rosuvastatin. Guidance is variant- and medicine-specific.
Reduced TPMT activity can increase the risk of severe thiopurine-related bone-marrow toxicity.
Guideline-supported gene–medicine association
The two listed markers do not cover all reduced-function alleles or all toxicity risks. NUDT15 status and blood-count monitoring are also relevant to thiopurine care.
This gene encodes the enzyme that metabolizes thiopurine drugs via S-adenosyl-L-methionine as the S-methyl donor and S-adenosyl-L-homocysteine as a byproduct. Thiopurine drugs such as 6-mercaptopurine are used as chemotherapeutic agents.
Function summary: NCBI Gene · TPMTMedicines discussed in guidance: Azathioprine, Mercaptopurine, Thioguanine. Guidance is variant- and medicine-specific.
Common regulatory variation can influence sensitivity to warfarin.
Guideline-supported gene–medicine association
The listed markers are only part of a warfarin assessment. CYP2C9 and other factors may matter, and genetic results do not replace INR monitoring.
This gene encodes the catalytic subunit of the vitamin K epoxide reductase complex, which is responsible for the reduction of inactive vitamin K 2,3-epoxide to active vitamin K in the endoplasmic reticulum membrane. Vitamin K is a required co-factor for carboxylation of glutamic acid residues by vitamin K-dependent gamma-carboxylase in blood-clotting enzymes.
Function summary: NCBI Gene · VKORC1Medicines discussed in guidance: Warfarin. Guidance is variant- and medicine-specific.
No genes match that search in this panel. Try another gene or condition, or clear the search.
Evidence is specific to a gene–condition relationship. Definitive, strong and moderate relationships appear in the main table. Supportive, limited, disputed and refuted assessments are separated; conflicting assessments are labelled rather than combined into a single positive claim.
Inheritance: autosomal dominant usually involves one disease-causing copy; autosomal recessive usually involves two disease-causing copies. X-linked, mitochondrial and other patterns need condition-specific interpretation. A gene may have more than one inheritance pattern.
A name in a panel is not a diagnosis. Everyone has most of these genes. Interpretation concerns a specific genetic change and its clinical significance. A variant of uncertain significance does not establish a cause.
Gene names: HGNC. Function summaries: NCBI Gene. Disease relationships: GenCC. Pharmacogenomic notes link to relevant prescribing resources. If no qualifying relationship is shown, this does not mean that no association exists. Reviewed 12 November 2026.
Gene or association labels are shown alongside the selected markers. Some associated markers are located outside the named gene.
| Gene / associated region | Markers |
|---|---|
| 6p21.33 | rs2844682 |
| ABCB1 | rs1045642, rs1128503 |
| ABCG2 | rs2231142 |
| ADRA2A | rs11195419, rs553668 |
| ADRB2 | rs1042713 |
| AMELX | hCV990000001 |
| ANKK1 | rs1800497 |
| APOE | rs429358, rs7412 |
| C11orf65 | rs11212617 |
| COL22A1 | rs6988229 |
| COMT | rs4680 |
| COQ2 | rs4693075 |
| CRHR2 | rs7793837 |
| CYP1A2 | rs12720461, rs2069514 |
| CYP2A6 | rs1801272, rs568811809 |
| CYP2B6 | rs28399499, rs3211371 |
| CYP2C19 | rs12248560, rs17884712 |
| CYP2C8 | rs10509681, rs1058930 |
| CYP2C9 | rs1057910, rs1799853 |
| CYP2D6 | CYP2D6 XN Exon 9, rs1065852 |
| CYP2E1 | rs2070672, rs2070673 |
| CYP3A4 | rs12721629, rs2740574 |
| CYP3A5 | rs10264272, rs28365083 |
| CYP4F2 | rs2108622 |
| DRD2 | rs1079598, rs1799732 |
| EPHX1 | rs1051740 |
| F2 | rs1799963 |
| F5 | rs6025 |
| FDPS | rs2297480 |
| FLOT1 | rs3909184 |
| GRIK4 | rs1954787 |
| HTR1A | rs6295 |
| HTR2A | rs6311, rs7997012 |
| HTR2C | rs3813929 |
| IFNL3 | rs12979860 |
| intergenic | rs3913290 |
| ITPA | rs1127354 |
| LTC4S | rs730012 |
| METTL21A | rs2952768 |
| MTHFR | rs1801131, rs1801133 |
| OPRM1 | rs1799971 |
| SCN1A | rs3812718 |
| SLC6A2 | rs12708954, rs3785143 |
| SLCO1B1 | rs4149056 |
| TPMT | rs1142345, rs1800460 |
| VKORC1 | rs9923231, rs9934438 |
| Additional chromosome 19 marker | rs8099917 |
In clinical context
Choosing a test means considering both the genes or regions examined and the types of changes it can detect.
Understanding gene–medicine associationsYour next step
We’ll discuss the clinical question and confirm testing arrangements, sample requirements, costs and reporting times.